Evidence map›Paper›PMID 28936810›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2017

Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.

B Weixler, F Renetseder, I Facile, N Tosti, E Cremonesi, A Tampakis, T Delko, S Eppenberger-Castori, A Tzankov, G Iezzi and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

B WeixlerDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
F RenetsederDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
I FacileDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
N TostiInstitute of Pathology, University of Basel, Basel, Switzerland.
E CremonesiDepartment of Biomedicine, University of Basel, Basel, Switzerland.
A TampakisDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
T DelkoDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
S Eppenberger-CastoriInstitute of Pathology, University of Basel, Basel, Switzerland.
A TzankovInstitute of Pathology, University of Basel, Basel, Switzerland.
G IezziDepartment of Biomedicine, University of Basel, Basel, Switzerland.
C KettelhackDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
S D SoysalDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
U von HolzenGoshen Center for Cancer Care, Indiana University School of Medicine South Bend, Goshen, IN, USA.
G C SpagnoliDepartment of Biomedicine, University of Basel, Basel, Switzerland.
L TerraccianoInstitute of Pathology, University of Basel, Basel, Switzerland.
L TornilloInstitute of Pathology, University of Basel, Basel, Switzerland.
Raoul A DroeserDepartment of Surgery, University Hospital Basel, Basel, Switzerland. Raoul.Droeser@usb.ch.
S DästerDepartment of Surgery, University Hospital Basel, Basel, Switzerland.
University Hospital of Basel · CHUniversity of Basel · CHMike and Josie Harper Cancer Research Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe CXCL12-CXCR4 chemokine axis plays an important role in cell trafficking as well as in tumor progression. In colorectal cancer (CRC), the chemokine receptor CXCR4 has been shown to be an unfavorable prognostic factor in some studies, however, the role of its activated (phosphorylated) form, pCXCR4, has not yet been evaluated. Here, we aimed to investigate the prognostic value of CXCR4 and pCXCR4 in a large cohort of CRC patients. PATIENTS AND

methodsA tissue microarray (TMA) of 684 patient specimens of primary CRCs was analyzed by immunohistochemistry (IHC) for the expression of CXCR4 and pCXCR4 by tumor cells and tumor-infiltrating immune cells (TICs).

resultsThe combined high expression of CXCR4 and pCXCR4 showed a favorable 5-year overall survival rate (68%; 95%CI = 59-76%) compared to tumors showing a high expression of CXCR4 only (48%; 95%CI = 41-54%). High expression of pCXCR4 was significantly associated with a favorable prognosis in a test and validation group (p = 0.015 and p = 0.0001). Moreover, we found that CRCs with a high density of pCXCR4+ tumor-infiltrating immune cells (TICs) also showed a favorable prognosis in a test and validation group (p = 0.054 and p = 0.004). Univariate Cox regression analysis for TICs revealed that a high density of pCXCR4+ TICs was a favorable prognostic marker for overall survival (HR = 0.97,95%CI = 0.96-1.00; p = 0.01). In multivariate Cox regression survival analyses a high expression of pCXCR4 in tumor cells lost its association with a better overall survival (HR = 0.99; 95%CI = 0.99-1.00, p = 0.098).

conclusionOur results show that high densities of CXCR4 and pCXCR4 positive TICs are favorable prognostic factors in CRC.

Indexed as

Colorectal NeoplasmsConfidence IntervalsHumansImmunohistochemistryPhosphorylationProportional Hazards ModelsReceptors, CXCR4Retrospective StudiesSignal TransductionSoftwareSurvival RateTissue Array AnalysisReceptors, CXCR4Colorectal cancerCRCCXCR4pCXCR4Prognostic significance

Identifiers

PMID28936810
PMCPMC13001541
OpenAlexW2757235467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.